Designation of chitosan nano-vaccine based on MxiH antigen of Shigella flexneri with increased immunization capacity

Gilavand, Farhad; Marzban, Abdolrazagh; Ebrahimipour, Gholamhossein; Soleimani, Neda; Goudarzi, Mehdi

doi:10.1016/j.carbpol.2019.115813

Cited by 27 publications

(19 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… Mice passive immunity protection [110] Self-assembled proteinaceous nanoparticles O-polysaccharide — s.c. Mice 100% of animals surviving [111] Chitosan MxiH — i.n. Mice 60% of animals surviving, compared with 10% of controls [112] Chitosan NF N-IpaD — i.n. Guinea pigs 93.75% protective efficacy against ocular challenge in guinea pigs [113] TMC nanoparticles N-IpaD — Oral Guinea pigs 83.3% protection against ocular challenge in guinea pigs [114] V. cholerae OMVs OMV components — Oral, i.n., or i.p.…”

Section: Bacterial Infectious Diseases and Advanced Delivery Systemsmentioning

confidence: 99%

“…As an alternative to the oral route for chitosan particles without an additional protection from acid degradation, direct nasal immunity may stimulate the systemic and intestinal IgA immune responses. A study showed that the loading of recombinant Shigella MxiH antigen into chitosan nanoparticles resulted in enhanced humoral and mucosal immune responses in intranasally immunized mice [112] . In addition, various chitosan-based delivery systems are available.…”

Section: Bacterial Infectious Diseases and Advanced Delivery Systemsmentioning

confidence: 99%

See 1 more Smart Citation

Prophylactic vaccine delivery systems against epidemic infectious diseases

Pan¹,

Yue

Zhu³

et al. 2021

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Prophylactic vaccines have evolved from traditional whole-cell vaccines to safer subunit vaccines. However, subunit vaccines still face problems, such as poor immunogenicity and low efficiency, while traditional adjuvants are usually unable to meet specific response needs. Advanced delivery vectors are important to overcome these barriers; they have favorable safety and effectiveness, tunable properties, precise location, and immunomodulatory capabilities. Nevertheless, there has been no systematic summary of the delivery systems to cover a wide range of infectious pathogens. We herein summarized and compared the delivery systems for major or epidemic infectious diseases caused by bacteria, viruses, fungi, and parasites. We also included the newly licensed vaccines (e.g., COVID-19 vaccines) and those close to licensure. Furthermore, we highlighted advanced delivery systems with high efficiency, cross-protection, or long-term protection against epidemic pathogens, and we put forward prospects and thoughts on the development of future prophylactic vaccines.

show abstract

Section: Bacterial Infectious Diseases and Advanced Delivery Systemsmentioning

confidence: 99%

Section: Bacterial Infectious Diseases and Advanced Delivery Systemsmentioning

confidence: 99%

Prophylactic vaccine delivery systems against epidemic infectious diseases

Pan¹,

Yue

Zhu³

et al. 2021

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

show abstract

“…Chitosan nanoparticles loaded with the recombinant MxiH antigen of Shigella flexneri (a gram-negative bacterium, and the cause of shigellosis in humans) were tested on mice, intranasally, and an increase in IgG and IgA antibodies was obtained compared to the control group. The use of the polymer in antigen administration has led to an increase in cellular uptake from the nasal epithelium and M cells; thus, humoral and mucosal immunity is stimulated due to chitosan, which indicates that chitosan-based nasal vaccines have a superior immunogenic effect [ 112 ].…”

Section: Chitosan In the Development Of Intranasal Vaccinesmentioning

confidence: 99%

New Opportunity to Formulate Intranasal Vaccines and Drug Delivery Systems Based on Chitosan

Popescu

Ghica

Dinu-Pîrvu

et al. 2020

IJMS

View full text Add to dashboard Cite

In an attempt to develop drug delivery systems that bypass the blood–brain barrier (BBB) and prevent liver and intestinal degradation, it was concluded that nasal medication meets these criteria and can be used for drugs that have these drawbacks. The aim of this review is to present the influence of the properties of chitosan and its derivatives (mucoadhesion, permeability enhancement, surface tension, and zeta potential) on the development of suitable nasal drug delivery systems and on the nasal bioavailability of various active pharmaceutical ingredients. Interactions between chitosan and proteins, lipids, antigens, and other molecules lead to complexes that have their own applications or to changing characteristics of the substances involved in the bond (conformational changes, increased stability or solubility, etc.). Chitosan and its derivatives have their own actions (antibacterial, antifungal, immunostimulant, antioxidant, etc.) and can be used as such or in combination with other molecules from the same class to achieve a synergistic effect. The applicability of the properties is set out in the second part of the paper, where nasal formulations based on chitosan are described (vaccines, hydrogels, nanoparticles, nanostructured lipid carriers (NLC), powders, emulsions, etc.).

show abstract

“…The zeta potential of NP was measured using a zeta potential analyzer (Zeta plus, Brookhaven Instruments Co, New York, NY, USA). All zeta estimations were determined at 25 • C in an electric field of 11.00 V/cm [39].…”

Section: Preparation Of Antigen-loaded Plga and Cs Npmentioning

confidence: 99%

Nanoparticles (PLGA and Chitosan)-Entrapped ADP-Ribosylation Factor 1 of Haemonchus contortus Enhances the Immune Responses in ICR Mice

et al. 2020

View full text Add to dashboard Cite

ADP-ribosylation factor 1 (HcARF1) is one of the Haemonchus contortus (H. contortus) excretory/secretory proteins involved in modulating the immune response of goat peripheral blood mononuclear cells (PBMC). Here, we evaluated the immunogenic potential of recombinant HcARF1 (rHcARF1) against H. contortus infection in Institute of Cancer Research (ICR) mice. Briefly, rHcARF1 was entrapped in poly (D, L-lactide-co-glycolide) (PLGA) and chitosan (CS) nanoparticles (NP) and injected into mice as a vaccine. Fifty-six ICR mice were assigned randomly into seven groups, with eight animals in each group, and they were vaccinated subcutaneously. At the end of the experiment (14th day), the blood and the spleen were collected from euthanized mice to detect lymphocyte proliferation, cytokine analysis, and the production of antigen-specific antibodies. Scanning electron microscope was used to determine the size, morphology, and zeta potential of nanoparticles. Flow cytometry was performed, which presented the increase percentages of CD4+ T cells (CD3e+CD4+), CD8+ T cells (CD3e+CD8+) and dendritic cells (CD11c+CD83+, CD11c+CD86+) in mice vaccinated with rHcARF1+PLGA NP. Immunoassay analysis show raised humoral (Immunoglobulin (Ig)G1, IgG2a, IgM) and cell-mediated immune response (Interleukin (IL)-4, IL-12, and IL-17, and Interferon (IFN)-γ) induced by rHcARF1+PLGA NP. Experimental groups that were treated with the antigen-loaded NP yield higher lymphocyte proliferation than the control groups. Based on these results, we could propose that the rHcARF1 encapsulated in NP could stimulate a strong immune response in mice rather than administering alone against the infection of H. contortus.

show abstract

Designation of chitosan nano-vaccine based on MxiH antigen of Shigella flexneri with increased immunization capacity

Cited by 27 publications

References 36 publications

Prophylactic vaccine delivery systems against epidemic infectious diseases

Prophylactic vaccine delivery systems against epidemic infectious diseases

New Opportunity to Formulate Intranasal Vaccines and Drug Delivery Systems Based on Chitosan

Nanoparticles (PLGA and Chitosan)-Entrapped ADP-Ribosylation Factor 1 of Haemonchus contortus Enhances the Immune Responses in ICR Mice

Contact Info

Product

Resources

About